Increased serum angiopoietin-like 6 ahead of metabolic syndrome in a prospective cohort study

Jun Namkung, Joon Hyung Sohn, Jae Seung Chang, Sang Wook Park, Jang Young Kim, Sang Baek Koh, In Deok Kong, Kyu Sang Park

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Background: Despite being an anti-obesity hepatokine, the levels of serum angiopoietin-like 6 (ANGPTL6) are elevated in various metabolic diseases. Thus, ANGPTL6 expression may reflect metabolic burden and may have compensatory roles. This study investigated the association between serum ANGPTL6 levels and new-onset metabolic syndrome. Methods: In total, 221 participants without metabolic syndrome were randomly selected from a rural cohort in Korea. Baseline serum ANGPTL6 levels were measured using an enzyme-linked immunosorbent assay. Anthropometric and biochemical markers were analyzed before and after follow-up examinations. Results: During an average follow-up period of 2.75 (interquartile range, 0.76) years, 82 participants (37.1%) presented new-onset metabolic syndrome and had higher ANGPTL6 levels before onset than those without metabolic syndrome (48.03±18.84 ng/mL vs. 64.75±43.35 ng/mL, P=0.001). In the multivariable adjusted models, the odds ratio for the development of metabolic syndrome in the highest quartile of ANGPTL6 levels was 3.61 (95% confidence interval, 1.27 to 10.26). The use of ANGPTL6 levels in addition to the conventional components improved the prediction of new-onset metabolic syndrome (area under the receiver operating characteristic curve: 0.775 vs. 0.807, P=0.036). Conclusion: Increased serum ANGPTL6 levels precede the development of metabolic syndrome and its components, including low high density lipoprotein, high triglyceride, and high glucose levels, which have an independent predictive value for metabolic syndrome.

Original languageEnglish
Pages (from-to)521-529
Number of pages9
JournalDiabetes and Metabolism Journal
Volume43
Issue number4
DOIs
Publication statusPublished - 2019 Aug 1

Fingerprint

Angiopoietins
Cohort Studies
Prospective Studies
Serum
Metabolic Diseases
HDL Lipoproteins
Korea
LDL Lipoproteins
ROC Curve
Triglycerides
Obesity
Biomarkers
Enzyme-Linked Immunosorbent Assay
Odds Ratio
Confidence Intervals
Glucose

All Science Journal Classification (ASJC) codes

  • Endocrinology, Diabetes and Metabolism

Cite this

Namkung, Jun ; Sohn, Joon Hyung ; Chang, Jae Seung ; Park, Sang Wook ; Kim, Jang Young ; Koh, Sang Baek ; Kong, In Deok ; Park, Kyu Sang. / Increased serum angiopoietin-like 6 ahead of metabolic syndrome in a prospective cohort study. In: Diabetes and Metabolism Journal. 2019 ; Vol. 43, No. 4. pp. 521-529.
@article{367db1244bf34385ad029ce9b934fb82,
title = "Increased serum angiopoietin-like 6 ahead of metabolic syndrome in a prospective cohort study",
abstract = "Background: Despite being an anti-obesity hepatokine, the levels of serum angiopoietin-like 6 (ANGPTL6) are elevated in various metabolic diseases. Thus, ANGPTL6 expression may reflect metabolic burden and may have compensatory roles. This study investigated the association between serum ANGPTL6 levels and new-onset metabolic syndrome. Methods: In total, 221 participants without metabolic syndrome were randomly selected from a rural cohort in Korea. Baseline serum ANGPTL6 levels were measured using an enzyme-linked immunosorbent assay. Anthropometric and biochemical markers were analyzed before and after follow-up examinations. Results: During an average follow-up period of 2.75 (interquartile range, 0.76) years, 82 participants (37.1{\%}) presented new-onset metabolic syndrome and had higher ANGPTL6 levels before onset than those without metabolic syndrome (48.03±18.84 ng/mL vs. 64.75±43.35 ng/mL, P=0.001). In the multivariable adjusted models, the odds ratio for the development of metabolic syndrome in the highest quartile of ANGPTL6 levels was 3.61 (95{\%} confidence interval, 1.27 to 10.26). The use of ANGPTL6 levels in addition to the conventional components improved the prediction of new-onset metabolic syndrome (area under the receiver operating characteristic curve: 0.775 vs. 0.807, P=0.036). Conclusion: Increased serum ANGPTL6 levels precede the development of metabolic syndrome and its components, including low high density lipoprotein, high triglyceride, and high glucose levels, which have an independent predictive value for metabolic syndrome.",
author = "Jun Namkung and Sohn, {Joon Hyung} and Chang, {Jae Seung} and Park, {Sang Wook} and Kim, {Jang Young} and Koh, {Sang Baek} and Kong, {In Deok} and Park, {Kyu Sang}",
year = "2019",
month = "8",
day = "1",
doi = "10.4093/dmj.2018.0080",
language = "English",
volume = "43",
pages = "521--529",
journal = "Diabetes and Metabolism Journal",
issn = "2233-6079",
publisher = "Korean Diabetes Association",
number = "4",

}

Increased serum angiopoietin-like 6 ahead of metabolic syndrome in a prospective cohort study. / Namkung, Jun; Sohn, Joon Hyung; Chang, Jae Seung; Park, Sang Wook; Kim, Jang Young; Koh, Sang Baek; Kong, In Deok; Park, Kyu Sang.

In: Diabetes and Metabolism Journal, Vol. 43, No. 4, 01.08.2019, p. 521-529.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Increased serum angiopoietin-like 6 ahead of metabolic syndrome in a prospective cohort study

AU - Namkung, Jun

AU - Sohn, Joon Hyung

AU - Chang, Jae Seung

AU - Park, Sang Wook

AU - Kim, Jang Young

AU - Koh, Sang Baek

AU - Kong, In Deok

AU - Park, Kyu Sang

PY - 2019/8/1

Y1 - 2019/8/1

N2 - Background: Despite being an anti-obesity hepatokine, the levels of serum angiopoietin-like 6 (ANGPTL6) are elevated in various metabolic diseases. Thus, ANGPTL6 expression may reflect metabolic burden and may have compensatory roles. This study investigated the association between serum ANGPTL6 levels and new-onset metabolic syndrome. Methods: In total, 221 participants without metabolic syndrome were randomly selected from a rural cohort in Korea. Baseline serum ANGPTL6 levels were measured using an enzyme-linked immunosorbent assay. Anthropometric and biochemical markers were analyzed before and after follow-up examinations. Results: During an average follow-up period of 2.75 (interquartile range, 0.76) years, 82 participants (37.1%) presented new-onset metabolic syndrome and had higher ANGPTL6 levels before onset than those without metabolic syndrome (48.03±18.84 ng/mL vs. 64.75±43.35 ng/mL, P=0.001). In the multivariable adjusted models, the odds ratio for the development of metabolic syndrome in the highest quartile of ANGPTL6 levels was 3.61 (95% confidence interval, 1.27 to 10.26). The use of ANGPTL6 levels in addition to the conventional components improved the prediction of new-onset metabolic syndrome (area under the receiver operating characteristic curve: 0.775 vs. 0.807, P=0.036). Conclusion: Increased serum ANGPTL6 levels precede the development of metabolic syndrome and its components, including low high density lipoprotein, high triglyceride, and high glucose levels, which have an independent predictive value for metabolic syndrome.

AB - Background: Despite being an anti-obesity hepatokine, the levels of serum angiopoietin-like 6 (ANGPTL6) are elevated in various metabolic diseases. Thus, ANGPTL6 expression may reflect metabolic burden and may have compensatory roles. This study investigated the association between serum ANGPTL6 levels and new-onset metabolic syndrome. Methods: In total, 221 participants without metabolic syndrome were randomly selected from a rural cohort in Korea. Baseline serum ANGPTL6 levels were measured using an enzyme-linked immunosorbent assay. Anthropometric and biochemical markers were analyzed before and after follow-up examinations. Results: During an average follow-up period of 2.75 (interquartile range, 0.76) years, 82 participants (37.1%) presented new-onset metabolic syndrome and had higher ANGPTL6 levels before onset than those without metabolic syndrome (48.03±18.84 ng/mL vs. 64.75±43.35 ng/mL, P=0.001). In the multivariable adjusted models, the odds ratio for the development of metabolic syndrome in the highest quartile of ANGPTL6 levels was 3.61 (95% confidence interval, 1.27 to 10.26). The use of ANGPTL6 levels in addition to the conventional components improved the prediction of new-onset metabolic syndrome (area under the receiver operating characteristic curve: 0.775 vs. 0.807, P=0.036). Conclusion: Increased serum ANGPTL6 levels precede the development of metabolic syndrome and its components, including low high density lipoprotein, high triglyceride, and high glucose levels, which have an independent predictive value for metabolic syndrome.

UR - http://www.scopus.com/inward/record.url?scp=85072109926&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85072109926&partnerID=8YFLogxK

U2 - 10.4093/dmj.2018.0080

DO - 10.4093/dmj.2018.0080

M3 - Article

AN - SCOPUS:85072109926

VL - 43

SP - 521

EP - 529

JO - Diabetes and Metabolism Journal

JF - Diabetes and Metabolism Journal

SN - 2233-6079

IS - 4

ER -